He, Jianfei
Steffen, Jonas Hyld
Thulstrup, Peter Waaben
Pedersen, Jannik Nedergaard
Sauerland, Max B.
Otzen, Daniel E.
Hawkins, Clare L.
Gourdon, Pontus
Davies, Michael J.
Hägglund, Per
Funding for this research was provided by:
China Scholarship Council
Novo Nordisk Fonden (NNF13OC0004294)
Natur og Univers, Det Frie Forskningsråd (DFF-7014-00047)
Carlsbergfondet (CF19-0451)
Article History
Received: 17 June 2022
Accepted: 13 December 2022
First Online: 21 December 2022
Competing interests
: Prof. Davies reports declares consultancy contracts with Novo Nordisk A/S, and is a founder and shareholder in Seleno Therapeutics plc. These funders had no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. All other authors declare no conflicts of interest.